News coverage about NCI (NASDAQ:NCIT) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. NCI earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave media headlines about the information technology services provider an impact score of 44.482885506287 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
NCIT has been the subject of a number of recent research reports. Cowen set a $24.00 price objective on NCI and gave the stock a “buy” rating in a research note on Thursday, August 17th. Zacks Investment Research cut NCI from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $18.33.
NCI (NASDAQ NCIT) opened at $20.00 on Friday. NCI has a 52-week low of $10.98 and a 52-week high of $21.40.
NCI, Inc is a provider of enterprise services and solutions to defense, intelligence, healthcare and civilian government agencies. The Company provides information technology (IT), and professional services and solutions by leveraging its core service offerings, which include cloud computing and IT infrastructure optimization; cybersecurity and information assurance; engineering and logistics support; enterprise information management and advanced analytics; health IT and medical support; IT service management; modeling, simulation, and training, and agile development and integration.
What are top analysts saying about NCI Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NCI Inc and related companies.